{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:16Z","timestamp":1794565516519,"version":"4.9.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec id=\"ab-csc260001-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Magnetic resonance imaging (MRI) is routinely used in prostate cancer diagnosis, but there is uncertainty about its optimal use in population-level screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-csc260001-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide consensus recommendations on the acquisition, interpretation, and reporting of prostate MRI for cancer screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-csc260001-3\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of randomized clinical trials and prospective cohort studies evaluating MRI for prostate cancer screening was conducted for these international consensus recommendations. A search of PubMed, CENTRAL, Scopus, Web of Science, and ClinicalTrials.gov, citation searching, and consultation with experts was performed in September 2024. Studies performing upfront MRI for the purpose of prostate cancer screening were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-csc260001-4\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>A total of 6 studies were identified and included 1919 participants, of whom 1426 underwent upfront screening MRI. Most studies used 3.0-T non\u2013contrast-enhanced MRI. The pooled biopsy recommendation rate was 19.2% (95% CI, 11.7-26.7), with grade group (GG) 2 or higher prostate cancer detection of 6.0% (95% CI, 3.1-9.0) and GG1 cancer detection of 1.4% (95% CI, 0.7-2.2). The positive predictive value for GG2 or higher cancer was 36.3% (95% CI, 21.1-51.4). Findings informed a RAND\/UCLA Appropriateness Method consensus exercise used to produce the Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM) recommendations. A total of 21 experts (8 urologists, 11 radiologists, and 2 pathologists from 6 countries) were included on the panel. Among 323 consensus statements, 235 (72.8%) reached agreement. If MRI is used in screening, it is recommended for men with an estimated life expectancy greater than 10 years and aged 50 to 70 years or from age 45 years in Black men. Screening MRI should be performed in men after a prostate-specific antigen (PSA) test, but there was no consensus on the optimal PSA threshold. Non\u2013contrast-enhanced MRI with only T2-weighted and diffusion-weighted imaging was considered appropriate, with a maximum acceptable acquisition time of 15 minutes. The stage-gated (2-step) approach to reporting, where all MRI sequences are only revealed (second step) if a concordant focal lesion is identified on axial T2-weighted and high b-value diffusion imaging (first step), was recommended. Repeat screening should be risk stratified according to patient characteristics. Screening MRI should only be performed in accredited centers with radiologists meeting minimum reporting requirements and quality standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-csc260001-5\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The PRISM consensus recommendations provide standardized expert guidance on the use of MRI in prostate cancer screening trials and future screening programs, including abbreviated non\u2013contrast-enhanced MRI protocols, recommended screening intervals, stage-gated reporting, and quality assurance standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.1711","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:00:17Z","timestamp":1781190017000},"page":"881","source":"Crossref","is-referenced-by-count":4,"title":["Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM)"],"prefix":"10.1001","volume":"12","author":[{"given":"Nikhil","family":"Mayor","sequence":"first","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Light","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Gopalakrishnan","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Cullen","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rawlins","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Sonigra-Patel","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Thorley","sequence":"additional","affiliation":[{"name":"Division of Surgery & Interventional Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences, University of Gothenburg, G\u00f6teborg, Sweden"},{"name":"Department of Urology, Sahlgrenska University Hospital, G\u00f6teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Dudderidge","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[{"name":"Division of Surgery & Interventional Science, University College London, London, United Kingdom"},{"name":"Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giganti","sequence":"additional","affiliation":[{"name":"Division of Surgery & Interventional Science, University College London, London, United Kingdom"},{"name":"Department of Radiology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman","family":"Haider","sequence":"additional","affiliation":[{"name":"Department of Pathology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoom A.","family":"Haider","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging. Sinai Health System, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hulson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amish","family":"Lakhani","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom"},{"name":"Paul Strickland Scanner Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Moore","sequence":"additional","affiliation":[{"name":"Division of Surgery & Interventional Science, University College London, London, United Kingdom"},{"name":"Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nordstrom","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institute & Dept Clinical Sciences, Danderyd Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[{"name":"Paul Strickland Scanner Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[{"name":"North West London Pathology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Valerio","sequence":"additional","affiliation":[{"name":"Department of Urology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhna","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Withey","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[{"name":"Division of Surgery & Interventional Science, University College London, London, United Kingdom"},{"name":"Department of Radiology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur T.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van der Meulen","sequence":"additional","affiliation":[{"name":"Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London, London, United Kingdom"},{"name":"Urology Department, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10437","key":"csc260001r1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases.","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"csc260001r2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2009.07.018","article-title":"Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).","volume":"56","author":"Roobol","year":"2009","journal-title":"Eur Urol"},{"issue":"1","key":"csc260001r3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer.","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"csc260001r4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/bju.15899","article-title":"The Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) prostate cancer diagnostic pathway.","volume":"131","author":"Eldred-Evans","year":"2023","journal-title":"BJU Int"},{"issue":"3","key":"csc260001r5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.eururo.2025.11.024","article-title":"Primary noncontrast magnetic resonance imaging for prostate cancer screening: a randomized clinical trial (PROSA).","volume":"89","author":"Messina","year":"2026","journal-title":"Eur Urol"},{"issue":"12","key":"csc260001r6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI.","volume":"391","author":"Hugosson","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"csc260001r8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","article-title":"Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.","volume":"59","author":"Dickinson","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"csc260001r9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2024.02.001","article-title":"The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): a systematic review and international consensus recommendations.","volume":"85","author":"Light","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"csc260001r10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations\u2014a report of a European School of Oncology Task Force.","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"issue":"1081","key":"csc260001r11","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170577","article-title":"UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer.","volume":"91","author":"Barnes","year":"2018","journal-title":"Br J Radiol"},{"issue":"1","key":"csc260001r12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bju.14361","article-title":"National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection\u2014recommendations from a UK consensus meeting.","volume":"122","author":"Brizmohun Appayya","year":"2018","journal-title":"BJU Int"},{"issue":"3","key":"csc260001r13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bju.15285","article-title":"Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.","volume":"127","author":"Barrett","year":"2021","journal-title":"BJU Int"},{"issue":"3","key":"csc260001r14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer.","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"csc260001r15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","article-title":"Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis.","volume":"10","author":"Fazekas","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"csc260001r16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"2","key":"csc260001r17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.juro.2016.01.114","article-title":"A pilot study to evaluate the role of magnetic resonance imaging for prostate cancer screening in the general population.","volume":"196","author":"Nam","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"csc260001r18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","article-title":"Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study.","volume":"7","author":"Eldred-Evans","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"csc260001r19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000057","article-title":"Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study.","volume":"2","author":"Moore","year":"2023","journal-title":"BMJ Oncol"},{"issue":"11","key":"csc260001r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059482","article-title":"Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.","volume":"12","author":"Nam","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"csc260001r21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00330-023-10019-1","article-title":"Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial\u2014Prostate Cancer Secondary Screening in Sapienza (PROSA).","volume":"34","author":"Messina","year":"2024","journal-title":"Eur Radiol"},{"issue":"2","key":"csc260001r22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.euf.2024.02.006","article-title":"Opportunistic prostate cancer screening with biparametric magnetic resonance imaging (VISIONING).","volume":"10","author":"Wetterauer","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"3","key":"csc260001r23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System Version 2.1: 2019 update of Prostate Imaging Reporting and Data System Version 2.","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"csc260001r24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bju.16155","article-title":"Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?","volume":"133","author":"Mayor","year":"2024","journal-title":"BJU Int"},{"issue":"4","key":"csc260001r25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/fampra\/cmab117","article-title":"Family history recording in UK general practice: the lIFeLONG study.","volume":"39","author":"Dineen","year":"2022","journal-title":"Fam Pract"},{"issue":"731","key":"csc260001r26","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.3399\/BJGP.2022.0235","article-title":"Development of a modified Cambridge Multimorbidity Score for use with SNOMED CT: an observational English primary care sentinel network study.","volume":"73","author":"Tsang","year":"2023","journal-title":"Br J Gen Pract"},{"issue":"3","key":"csc260001r27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/afw039","article-title":"Development and validation of an electronic frailty index using routine primary care electronic health record data.","volume":"45","author":"Clegg","year":"2016","journal-title":"Age Ageing"},{"issue":"22","key":"csc260001r28","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter.","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"csc260001r29","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","article-title":"ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training.","volume":"30","author":"de Rooij","year":"2020","journal-title":"Eur Radiol"},{"issue":"3","key":"csc260001r30","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00330-025-11837-1","article-title":"Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).","volume":"36","author":"Thorley","year":"2026","journal-title":"Eur Radiol"},{"issue":"13","key":"csc260001r32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study.","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"csc260001r33","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2013.05.030","article-title":"Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.","volume":"64","author":"Roobol","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"csc260001r34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","article-title":"A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.","volume":"84","author":"de Vos","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"csc260001r35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2024.01.017","article-title":"Prostate cancers in the prostate-specific antigen interval of 1.8-3 ng\/mL: results from the G\u00f6teborg-2 Prostate Cancer Screening Trial.","volume":"86","author":"M\u00f6ller","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"csc260001r36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","article-title":"An evaluation of screening pathways using a combination of magnetic resonance imaging and prostate-specific antigen: results from the IP1-PROSTAGRAM Study.","volume":"6","author":"Eldred-Evans","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"10438","key":"csc260001r37","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/S0140-6736(24)00912-7","article-title":"Prostate Cancer UK launches the TRANSFORM trial.","volume":"403","author":"Burki","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"csc260001r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54577","article-title":"Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3-MRI randomized clinical trial.","volume":"7","author":"Nordstr\u00f6m","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"csc260001r39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.eururo.2023.09.027","article-title":"Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: results from the first screening round of the PROBASE trial.","volume":"85","author":"Boschheidgen","year":"2024","journal-title":"Eur Urol"},{"issue":"17","key":"csc260001r40","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, Kallikrein panel, and MRI: the ProScreen randomized trial.","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"csc260001r41","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12250-4","article-title":"Diagnostic accuracy of a \u2018stage-gated\u2019 approach for reporting prostate screening MRI: \u201cis less more?\u201d.","author":"Thorley","journal-title":"Eur Radiol"},{"issue":"3","key":"csc260001r42","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2025.05.020","article-title":"Prostate cancer detection in younger men: a comparative analysis of systematic and magnetic resonance imaging-targeted biopsy in the PROBASE trial.","volume":"88","author":"Al-Monajjed","year":"2025","journal-title":"Eur Urol"},{"key":"csc260001r7","unstructured":"Trial of Randomised Approaches for National Screening FOR Men (TRANSFORM). ISRCTN identifier: ISRCTN13801649. Updated December 30, 2025. Accessed January 16, 2026. https:\/\/www.isrctn.com\/ISRCTN13801649"},{"key":"csc260001r31","unstructured":"European Association of Urology. PRAISE-U. Accessed January 17, 2026. https:\/\/uroweb.org\/praise-u"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2850487\/jamaoncology_mayor_2026_sc_260001_1787161676.05947.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:02:29Z","timestamp":1787238149000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2850487"}},"subtitle":["International Consensus Recommendations"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.1711","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}